Ibritumomab tiuxetan

替伊莫单抗

Report date: 2025/09/04 17:53:58

Base Information

Drug NameIbritumomab tiuxetan
Drug Alias Name替伊莫单抗Indium-111 Ibritumomab tiuxetan替依莫单抗Yttrium-90 ibritumomab tiuxetanMonoclonal antibody IDEC-Y2B8 +[19] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[9] 
Global Approved IndicationsLymphoma, Mantle-CellLymphoma, B-CellLymphoma, Non-Hodgkin
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2002/02/19
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesMundipharma KkSpectrum Pharmaceuticals IncAcrotech Biopharma Llc +[4] 
Inactive CompaniesCabyc SlBiogen IncNational Cancer Institute +[10] 
Active IndicationsLymphoma, Mantle-CellLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsWaldenstrom MacroglobulinemiaLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[6] 

Other Information

ATC CodeV10XX02
Related LinksWikipediaDrugBankKEGG